Evidence from credible sources supports the statement as accurate. Learn more in Methodology.
Documentation that the Administration has executed 16 agreements with pharmaceutical manufacturers and details of products/pricing effects.
Evidence from official and independent reporting supports the claim that, by mid‑January 2026, the Trump administration had secured 16 voluntary pricing deals with major pharmaceutical manufacturers aimed at aligning certain U.S. drug prices with those in other developed nations.
A White House fact sheet dated December 19, 2025 states that, since September 30, 2025, President Trump had announced 14 deals with major pharmaceutical manufacturers "to bring prices in line with those paid in other developed nations," under a most-favored-nation (MFN) framework. Subsequently, Johnson & Johnson reached an MFN pricing agreement with the administration announced on January 9, 2026, and AbbVie announced a similar MFN/TrumpRx agreement on January 12, 2026, bringing the total to 16 such deals with major drugmakers. Contemporaneous coverage by outlets such as CNBC and CBS News also notes that the White House had MFN agreements with 14 of the 17 largest drugmakers by December 19, with the J&J and AbbVie deals expanding that roster.
Verdict: True. The count of MFN-style pricing deals as of January 16, 2026 is corroborated by official White House documentation and multiple independent news and industry sources, supporting the statement that the administration had secured 16 such deals with major pharmaceutical manufacturers to align prices with those in other developed nations.